Lonza CEO steps down

Chairman Albert Baehny will take over for Marc Funk who is leaving for personal reasons

Lonza announced today that Marc Funk, CEO, will leave the company for personal reasons.

The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found.

Funk will stay until January 2020 to ensure a smooth hand-over.

In addition, for reasons of good governance, board member Christoph Maeder has been appointed Lead Independent Director by the Board.

Christoph Maeder, Lead Independent Director said: "Albert has agreed to lead the company on a temporary basis until a successor is in place, for which a search has commenced. The Board respects Marc's decision and would like to thank him for his service to Lonza and wish him well for his future endeavours."

Funk will stay until January 2020 to ensure a smooth hand-over

Albert Baehny, Chairman said: "I am committed to Lonza, its employees and all its stakeholders and I will ensure that I work in their best interests in the months ahead. The company has an exciting future in dynamic markets and I am keen to ensure that we maintain our momentum and capture all the opportunities available to us. I look forward to working with colleagues, customers, partners and other stakeholders in the coming months and also to working with the Board in the search for a new Chief Executive Officer to lead the company in the years ahead."

You may also like

Regulatory

UPDATE: US Pharmacopeia makes comments public on endotoxin testing overhaul

The USP has published the comments the organisation received in response to the addition of non-animal derived endotoxin testing methods, as well as an FAQ page on the issue
Cleaning

Lonza expands PyroCell pyrogen testing portfolio with two new rapid systems

Lonza has launched PyroCell MAT Rapid System and PyroCellMAT Human Serum (HS) Rapid System, two sustainable monocyte activation test (MAT) systems containing the new PeliKine Human IL-6 Rapid ELISA Kit
Analysis

Lonza to phase out traditional endotoxin testing LAL and TAL assay reader for new tech

The company has launched the Nebula Absorbance Reader that is a technologically advanced, high-performance replacement reader, which delivers results comparable to those typically found with the traditional method and will facilitate the smooth continuation of current pyrogen and endotoxin testing programmes
Pharmaceutical

Q&A: Lonza’s PyroCell Monocyte activation test

Lonza has launched the PyroCell MAT that uses human serum instead of foetal bovine serum for pharmaceutical testing, but how does it change the status quo?
Design & Build

Lonza commissions BAM for Chemelot mRNA facility renovation

Lonza has commissioned BAM to renovate the ground floor up to and including the second floor of its Brighthouse building 300 on the Brightlands Chemelot Campus
Cleaning

Q&A on Lonza’s new PyroCell Monocyte Activation Test

Speaking to Katrin Pauls from Lonza about the launch of the company's PyroCell MAT, which uses human serum instead of foetal bovine serum for pharmaceutical testing, and how it changes the status quo
Cleaning

Lonza debuts first multimode reader to streamline quantitative endotoxin detection

The global science company has launched the Nebula Multimode Reader, the first multimode reader qualified for use with Lonza’s turbidimetric, chromogenic and recombinant endotoxin detection methods
Subscribe now